Patents by Inventor Alan B. Northrup

Alan B. Northrup has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclic di-nucleotide compounds as sting agonists
    Patent number: 10766919
    Abstract: A class of polycyclic compounds of general formula (I), of general formula (I?), or of general formula (I?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: September 8, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, Andrew Marc Haidle, Timothy J. Henderson, James P. Jewell, Rui Liang, Jongwon Lim, Hong Liu, Min Lu, Alan B. Northrup, Ryan D. Otte, Tony Siu, Benjamin Wesley Trotter, Quang T. Truong, Shawn P. Walsh, Kake Zhao
  • Cyclic di-nucleotide compounds as STING agonists
    Patent number: 10759825
    Abstract: A class of polycyclic compounds of general formula (I), of general formula (I?), or of general formula (I?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: September 1, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, James P. Jewell, Jongwon Lim, Alan B. Northrup, Ryan D. Otte, Benjamin Wesley Trotter, Quang T. Truong, Shawn P. Walsh, Kake Zhao
  • Cyclic di-nucleotide compounds as STING agonists
    Patent number: 10738074
    Abstract: A class of polycyclic compounds of general formula (II), of general formula (II?), or of general formula (II?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3a, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: August 11, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, Andrew Marc Haidle, Timothy J. Henderson, James P. Jewell, Min Lu, Alan B. Northrup, Ryan D. Otte, Tony Siu, Benjamin Wesley Trotter, Quang T. Truong
  • CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
    Publication number: 20180244712
    Abstract: A class of polycyclic compounds of general formula (I), of general formula (I?), or of general formula (I?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Application
    Filed: February 1, 2018
    Publication date: August 30, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, Andrew Marc Haidle, Timothy J. Henderson, James P. Jewell, Rui Liang, Jongwon Lim, Hong Liu, Min Lu, Alan B. Northrup, Ryan D. Otte, Tony Siu, Benjamin Wesley Trotter, Quang T. Truong, Shawn P. Walsh, Kake Zhao
  • CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
    Publication number: 20180237469
    Abstract: A class of polycyclic compounds of general formula (I), of general formula (I?), or of general formula (I?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Application
    Filed: February 1, 2018
    Publication date: August 23, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, Andrew Marc Haidle, Timothy J. Henderson, James P. Jewell, Rui Liang, Jongwon Lim, Hong Liu, Min Lu, Alan B. Northrup, Ryan D. Otte, Tony Siu, Benjamin Wesley Trotter, Quang T. Truong, Shawn P. Walsh, Kake Zhao
  • CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
    Publication number: 20180230178
    Abstract: A class of polycyclic compounds of general formula (II), of general formula (II?), or of general formula (II?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3a, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Application
    Filed: August 11, 2016
    Publication date: August 16, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, Andrew Marc Haidle, Timothy J. Henderson, James P. Jewell, Min Lu, Alan B. Northrup, Ryan D. Otte, Tony Siu, Benjamin Wesley Trotter, Quang T. Truong
  • Inhibitors of IRAK4 activity
    Patent number: 9969749
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: May 15, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian M. Andresen, Jason D. Brubaker, Matthew L. Childers, Anthony Donofrio, Thierry Fischmann, Craig R. Gibeau, Solomon D. Kattar, Charles A. Lesburg, Jongwon Lim, John K. F. MacLean, Umar F. Mansoor, Alan B. Northrup, John M. Sanders, Luis Torres
  • Inhibitors of IRAK4 activity
    Patent number: 9943516
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: April 17, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian M. Andresen, Jason D. Brubaker, Anthony Donofrio, Thierry Fischmann, Craig R. Gibeau, Charles A. Lesburg, Jongwon Lim, John K. F. Maclean, Umar F. Mansoor, Alan B. Northrup, John M. Sanders, Graham F. Smith, Luis Torres
  • Inhibitors of IRAK4 activity
    Patent number: 9932350
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: April 3, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Jason D. Brubaker, Matthew L. Childers, Anthony Donofrio, Thierry Fischmann, Craig R. Gibeau, Solomon D. Kattar, Charles A. Lesburg, Jongwon Lim, John K. F. Maclean, Umar F. Mansoor, Alan B. Northrup, John M. Sanders, Graham F. Smith
  • Inhibitors of IRAK4 activity
    Patent number: 9926330
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: March 27, 2018
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Michael D. Altman, Jason D. Brubaker, Matthew L. Childers, Anthony Donofrio, Thierry Fischmann, Craig R. Gibeau, Solomon D. Kattar, Charles A. Lesburg, Jongwon Lim, John K. F. MacLean, Umar F. Mansoor, Alan B. Northrup, John M. Sanders, Graham F. Smith
  • Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
    Patent number: 9822107
    Abstract: The invention provides certain thiazole-substituted aminoheteroaryl compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein ring R1, R2, R3, R4, ring B, and the subscript r are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: November 21, 2017
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: Brian M. Andresen, Kenneth L. Arrington, Ryan D. Otte, John Michael Ellis, John W. Butcher, Alan B. Northrup, Joel S. Robichaud, Jacques Yves Gauthier, Jean-Francois Fournier
  • Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
    Patent number: 9783531
    Abstract: The invention provides certain thiazole-substituted aminoheteroaryl compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R3, R5, R6, A, Cy and the subscripts r, s, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: October 10, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michelle R. Machacek, Eric T. Romeo, Alan B. Northrup, Michael D. Altman
  • 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
    Patent number: 9775839
    Abstract: The invention provides certain pyrazine-2-carboxamide compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A, B, and X are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: October 3, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brandon Cash, John Michael Ellis, Matthew L. Maddess, Alan B. Northrup, Ryan D. Otte, Binyuan Sun
  • INHIBITORS OF IRAK4 ACTIVITY
    Publication number: 20170275297
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Application
    Filed: September 25, 2015
    Publication date: September 28, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Michael D. ALTMAN, Brian M. ANDRESEN, Jason D. BRUBAKER, Matthew L. CHILDERS, Anthony DONOFRIO, Thierry FISCHMANN, Craig R. GIBEAU, Solomon D. KATTAR, Charles A. LESBURG, Jongwon LIM, John K.F. MACLEAN, Umar F. MANSOOR, Alan B. NORTHRUP, John SANDERS, Graham F. SMITH, Luis TORRES
  • INHIBITORS OF IRAK4 ACTIVITY
    Publication number: 20170247388
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Application
    Filed: September 25, 2015
    Publication date: August 31, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: MICHAEL D. ALTMAN, JASON D. BRUBAKER, MATTHEW L. CHILDERS, ANTHONY DONOFRIO, THIERRY FISCHMANN, CRAIG R. GIBEAU, SOLOMON D. KATTAR, CHARLES A. LESBURG, JONGWON LIM, JOHN K.F. MACLEAN, UMAR F. MANSOOR, ALAN B. NORTHRUP, JOHN M. SANDERS, GRAHAM F. SMITH
  • Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
    Patent number: 9745295
    Abstract: The invention provides certain thiazole-substituted aminoheteroaryl compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, Y1, Y2, Y3, Y4, and R4 are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: August 29, 2017
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: Neville J. Anthony, Brian M. Andresen, Alan B. Northrup, Kaleen K. Childers, Anthony Donofrio, Thomas A. Miller, Yuan Liu, Michelle R. Machacek, Hyun Chong Woo, Kerrie B. Spencer, John Michael Ellis, Michael D. Altman, Eric T. Romeo, Daniel Guay, Jonathan Grimm, Marie-Eve Lebrun, Joel S. Robichaud, Liping Wang, Byron DuBois, Qiaolin Deng
  • INHIBITORS OF IRAK4 ACTIVITY
    Publication number: 20170217981
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibutors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Application
    Filed: September 25, 2015
    Publication date: August 3, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: MICHAEL D. ALTMAN, JASON D. BRUBAKER, MATTHEW L. CHILDERS, ANTHONY DONOFRIO, THIERRY FISCHMANN, CRAIG R. GIBEAU, SOLOMON D. KATTAR, CHARLES A. LESBURG, JONGWON LIM, JOHN K.F. MACLEAN, UMAR F. MANSOOR, ALAN B. NORTHRUP, JOHN M. SANDERS, GRAHAM F. SMITH
  • INHIBITORS OF IRAK4 ACTIVITY
    Publication number: 20170209446
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Application
    Filed: September 25, 2015
    Publication date: July 27, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: MICHAEL D. ALTMAN, BRIAN M. ANDRESEN, JASON D. BRUBAKER, ANTHONY DONOFRIO, THIERRY FISCHMANN, CRAIG R. GIBEAU, CHARLES A. LESBURG, JONGWON LIM, JOHN K.F. MACLEAN, UMAR F. MANSOOR, ALAN B. NORTHRUP, JOHN M. SANDERS, GRAHAM F. SMITH, LUIS TORRES
  • Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors
    Patent number: 9670196
    Abstract: The invention provides certain thiazole-substituted aminoheteroaryl compounds of the Formula (I) (I), or pharmaceutically acceptable salts thereof, wherein ring R1, R2, R3, R4, ring A, and the subscripts n1, n2, and r are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: June 6, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Thomas A. Miller, Alessia Petrocchi, Eric T. Romeo, Dilrukshi Vitharana, Solomon D. Kattar, Alan B. Northrup, Michael D. Altman, Neville J. Anthony
  • Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
    Patent number: 9598405
    Abstract: The invention provides certain thiazole-substituted aminopyridine compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, Cy, and the subscript t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: March 21, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian M. Andresen, Kenneth L. Arrington, Kaleen Konrad Childers, Maria Emilia Di Francesco, John Michael Ellis, Andrew M. Haidle, Yuan Liu, Alan B. Northrup, Brendan O'Boyle, Ryan D. Otte, Michael H. Reutershan, Dilrukshi Vitharana, Hyun Chong Woo